Revelation Biosciences Inc (REVB) Stock Price, Quote & News

Company Profile

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed...

Industry: Biotechnology

Sector: Healthcare

Phone: (650) 800-3717

Website: www.revbiosciences.com

Address:

4660 La Jolla Village Drive, Suite 100, San Diego, United States

SkyLonger Sep. 8 at 7:25 PM

$REVB only 1.7M Float see you tomorrow 🤙

0 · Reply

HyperBulls Sep. 8 at 7:08 PM

$REVB is next $OCTO

1 · Reply

StockFlips Sep. 6 at 12:11 PM

$BTBD this week’s juice 🥂 $REVB heating up !! 🫵

0 · Reply

Meksss Sep. 6 at 10:01 AM

$GRI $IBRX $KAPA $REVB $RNAZ

0 · Reply

Ataifanboymentalhealthz Sep. 5 at 11:20 PM

$GRI $IBRX $KAPA $REVB $RNAZ not sure about others but KAPA has two catalysts this month. If both good I expect good things . Lung cancer this weekend and the September 18 for prostate cancer

1 · Reply

makedatbread88 Sep. 5 at 10:58 PM

September known data catalysts to watch closely $RNAZ $REVB $KAPA $GRI $IBRX At least one of these will run hard let's see!

0 · Reply

Sstckr Sep. 5 at 3:42 PM

$REVB

0 · Reply

fisher04 Sep. 5 at 1:12 AM

$REVB already pretty up from my entry of 2.66$ .. lets continue tomorrow.

0 · Reply

makedatbread88 Sep. 4 at 11:55 PM

$REVB keep an eye here someone’s buying it into the close in after hours news could drop any day Data catalyst due this month

0 · Reply

StockFlips Sep. 4 at 7:22 PM

$REVB accumulation mode. Gemini data readout expected by end of September. (End of Q3).

0 · Reply

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

Jul 24, 2025, 9:00 AM EDT - 6 weeks ago

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

Jul 16, 2025, 9:00 AM EDT - 7 weeks ago

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Jul 1, 2025, 5:26 PM EDT - 2 months ago

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

May 29, 2025, 4:05 PM EDT - 3 months ago

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

May 29, 2025, 8:00 AM EDT - 3 months ago

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

May 23, 2025, 4:05 PM EDT - 3 months ago

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

May 8, 2025, 4:15 PM EDT - 4 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

Apr 29, 2025, 9:00 AM EDT - 4 months ago

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

Mar 17, 2025, 6:00 AM EDT - 6 months ago

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Mar 13, 2025, 6:00 AM EDT - 6 months ago

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

Mar 6, 2025, 4:15 PM EST - 6 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Feb 26, 2025, 6:00 AM EST - 6 months ago

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Feb 24, 2025, 6:00 AM EST - 7 months ago

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Jan 24, 2025, 6:00 AM EST - 8 months ago

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Jan 21, 2025, 6:00 AM EST - 8 months ago

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Jan 13, 2025, 6:00 AM EST - 8 months ago

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Jan 6, 2025, 6:00 AM EST - 8 months ago

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Dec 3, 2024, 8:38 AM EST - 9 months ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Dec 2, 2024, 6:00 AM EST - 10 months ago

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Nov 12, 2024, 6:00 AM EST - 10 months ago

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Nov 8, 2024, 4:15 PM EST - 10 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Sep 24, 2024, 6:00 AM EDT - 1 year ago

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Aug 21, 2024, 5:30 PM EDT - 1 year ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Aug 9, 2024, 4:15 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Jun 24, 2024, 9:00 AM EDT - 1 year ago

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Jun 13, 2024, 9:21 AM EDT - 1 year ago

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

May 10, 2024, 4:52 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

Mar 22, 2024, 4:15 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Mar 13, 2024, 9:00 AM EDT - 1 year ago

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Mar 12, 2024, 9:00 AM EDT - 1 year ago

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Mar 4, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Feb 13, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Feb 9, 2024, 8:35 AM EST - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In February

CNSP GILD ZLAB

Feb 5, 2024, 4:41 PM EST - 1 year ago

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

Feb 1, 2024, 6:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

Jan 30, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Jan 23, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

Nov 13, 2023, 4:05 PM EST - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023

Oct 12, 2023, 9:00 AM EDT - 2 years ago

Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies

Oct 4, 2023, 9:00 AM EDT - 2 years ago

Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference

Oct 2, 2023, 9:00 AM EDT - 2 years ago

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

Aug 11, 2023, 4:10 PM EDT - 2 years ago

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023

Jun 29, 2023, 9:00 AM EDT - 2 years ago

REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders

Jun 12, 2023, 4:15 PM EDT - 2 years ago

Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal

May 22, 2023, 9:00 AM EDT - 2 years ago

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress

Mar 30, 2023, 5:42 PM EDT - 2 years ago

Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress

Mar 13, 2023, 9:00 AM EDT - 2 years ago

Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board

Mar 6, 2023, 9:00 AM EST - 2 years ago

Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference

Feb 13, 2023, 4:20 PM EST - 2 years ago

Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering

SkyLonger Sep. 8 at 7:25 PM

$REVB only 1.7M Float see you tomorrow 🤙

0 · Reply

HyperBulls Sep. 8 at 7:08 PM

$REVB is next $OCTO

1 · Reply

StockFlips Sep. 6 at 12:11 PM

$BTBD this week’s juice 🥂 $REVB heating up !! 🫵

0 · Reply

Meksss Sep. 6 at 10:01 AM

$GRI $IBRX $KAPA $REVB $RNAZ

0 · Reply

Ataifanboymentalhealthz Sep. 5 at 11:20 PM

$GRI $IBRX $KAPA $REVB $RNAZ not sure about others but KAPA has two catalysts this month. If both good I expect good things . Lung cancer this weekend and the September 18 for prostate cancer

1 · Reply

makedatbread88 Sep. 5 at 10:58 PM

September known data catalysts to watch closely $RNAZ $REVB $KAPA $GRI $IBRX At least one of these will run hard let's see!

0 · Reply

Sstckr Sep. 5 at 3:42 PM

$REVB

0 · Reply

fisher04 Sep. 5 at 1:12 AM

$REVB already pretty up from my entry of 2.66$ .. lets continue tomorrow.

0 · Reply

makedatbread88 Sep. 4 at 11:55 PM

$REVB keep an eye here someone’s buying it into the close in after hours news could drop any day Data catalyst due this month

0 · Reply

StockFlips Sep. 4 at 7:22 PM

$REVB accumulation mode. Gemini data readout expected by end of September. (End of Q3).

0 · Reply

hassan101 Sep. 4 at 6:20 PM

$REVB Imagine the company announces successful study results, then applies to the FDA to move to the next phase, followed by entering into a major partnership with a leading pharmaceutical company. The market size for the disease targeted by Gemini is estimated at $30–50 billion annually, and we wish all patients a full recovery.☘️

0 · Reply

fisher04 Sep. 4 at 4:46 PM

$REVB in with starter ..will add dips

0 · Reply

makedatbread88 Sep. 4 at 3:59 PM

watching closely two super low float biotechs $REVB and $RNAZ Both only 600k floats, both have phase 1 data read outs due this month One of these should run, possibly both. Let's see what happens taking my chance regardless!

1 · Reply

fisher04 Sep. 3 at 4:21 PM

$REVB @StockFlips still here ??

1 · Reply

HyperBulls Sep. 3 at 12:36 PM

$REVB probably 24th

0 · Reply

CryptoSenderX Aug. 29 at 2:36 PM

$REVB It’s time??? 🪐 Sender was in $ETHZ I $YHC I $SBET I $STSS

1 · Reply

HyperBulls Aug. 29 at 5:11 AM

$REVB Safety and tolerability follow-up is typically 2–6 weeks, while side effect monitoring is 4–8 weeks. The data are expected to be presented in Q3 2025. Doesn’t this mean it should be sometime in July, August, or September? Why do you think it must be by the end of August? Am I misunderstanding? Please correct me if I’m wrong. Since it is already stated that the completion of dosing was in July, shouldn’t there be some time afterwards to observe potential side effects and toleration and preparation of rep after the results are collected.

1 · Reply

makedatbread88 Aug. 28 at 9:24 PM

$REVB tomorrow is the last trading day of the summer so maybe news tomorrow? Let’s see. If not tomorrow I think next week. Data is due! Read 👇👇👇

0 · Reply

SkyLonger Aug. 28 at 7:28 PM

$REVB tick tock ...

0 · Reply

makedatbread88 Aug. 28 at 1:55 PM

$REVB I am buying more here after reading their recent PRs it said data in the summer Well, tomorrow is the last day of August for trading/end of summer I think we get data results tomorrow if not next week let’s see! I am loading all dips

1 · Reply

hassan101 Aug. 28 at 12:31 PM

$REVB U

0 · Reply

SkyLonger Aug. 28 at 10:55 AM

$REVB

0 · Reply

Market Cap	4.88M
Revenue (ttm)	0.00
Net Income (ttm)	-15.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	84,600
Avg Vol	179,239
Day's Range	N/A - N/A
Shares Out	1.70M
Stochastic %K	83%
Beta	-0.04
Analysts	Strong Sell
Price Target	$40.73